OBJECTIVE: To investigate changes in cognitive function and clinical features following a switch from oral atypical antipsychotics (AAPs) to long-acting injectable @entity1090 (LAIR) in @entity1 with @entity161 . METHODS: Thirty-six @entity1 with @entity161 treated with oral AAPs participated in this open-label, 26-week study. Cognitive functions were measured at baseline and at 12 and 26 weeks. The secondary outcome measures included the Positive and Negative Syndrome Scale (PANSS), Social and Occupational Functioning Assessment Scale (SOFAS), @entity146 ( @entity146 ), and measurements for @entity21 . RESULTS: Significant improvements in cognitive function were observed in the backward Digit Span Test, Verbal Learning Test, Wisconsin Card Sorting Test, correct responses on the Continuous Performance Test, and @entity2205 Making Test part B following a switch to LAIR. Scores on the PANSS, SOFAS, @entity146 , and the Simpson-Angus Rating Scale also improved significantly. Most improvements in neurocognitive function were not correlated with clinical measures. @entity1017 and @entity4089 were the most common adverse events. CONCLUSIONS: Switching from oral AAPs to LAIR improved cognitive function including vigilance, verbal learning and memory, executive function, sustained attention, and visuomotor speed in @entity1 with @entity161 . It was also effective for improving @entity716 , social functioning, and insight.

Effects of switching to long-acting injectable XXXX from oral atypical antipsychotics on cognitive function in @entity1 with @entity161 .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity4089 :: ('MESH:D006966', 'Disease') :: ['hyperprolactinemia'] @entity146 :: ('MESH:D001523', 'Disease') :: ['Scale for Unawareness of Mental Disorder', 'SUMD'] @entity2205 :: ('8743', 'Gene') :: ['Trail'] @entity1017 :: ('MESH:D015430', 'Disease') :: ['Weight gain'] @entity161 :: ('MESH:D012559', 'Disease') :: ['schizophrenia'] @entity716 :: ('MESH:D011605', 'Disease') :: ['psychotic symptoms'] @entity21 :: ('MESH:D001480', 'Disease') :: ['extrapyramidal symptoms'] @entity1090 :: ('MESH:D018967', 'Chemical') :: ['risperidone']
@entity1090 :: (MESH:D018967,Chemical) :: ['risperidone']
